Intellia Therapeutics (NASDAQ: NTLA) revenue
Intellia Therapeutics reported revenue of $67.7m for fiscal 2025, 16.9% more than in fiscal 2024 ($57.9m). Since fiscal 2016 its revenue has grown by 310.6%, an average growth of 17.0% a year.
Intellia Therapeutics has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2021, −43.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $67.7m | +16.9% | −$441.0m | −651.7% |
| 2024 | $57.9m | +59.6% | −$534.3m | −923.1% |
| 2023 | $36.3m | −30.4% | −$515.3m | −1,420.5% |
| 2022 | $52.1m | +57.7% | −$458.2m | −879.0% |
| 2021 | $33.1m | −43.0% | −$267.9m | −810.4% |
| 2020 | $58.0m | +34.5% | −$136.6m | −235.5% |
| 2019 | $43.1m | +41.6% | −$106.4m | −246.8% |
| 2018 | $30.4m | +16.5% | −$90.9m | −298.6% |
| 2017 | $26.1m | +58.5% | −$69.6m | −266.3% |
| 2016 | $16.5m | — | −$32.2m | −195.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Intellia Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Intellia Therapeutics ranks 316th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Intellia Therapeutics, 16.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 314th | Personalis | $69.6m | −17.7% |
| 315th | Vir Biotechnology | $68.6m | −7.6% |
| 316th | Intellia Therapeutics | $67.7m | 16.9% |
| 317th | Kura Oncology | $67.5m | 25.2% |
| 318th | Enanta Pharmaceuticals | $65.3m | −3.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Intellia Therapeutics
- How much revenue did Intellia Therapeutics make in fiscal 2025?
- Intellia Therapeutics reported revenue of $67.7m for fiscal 2025, compared with $57.9m in fiscal 2024.
- How much has the revenue of Intellia Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $16.5m to $67.7m: 310.6% more, an average growth of 17.0% a year.
- What was the best year for revenue at Intellia Therapeutics?
- Of its last 10 fiscal years, fiscal 2025, with $67.7m.
- Where does Intellia Therapeutics rank in its sector by revenue?
- It ranks 316th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Intellia Therapeutics come from?
- From the annual report (Form 10-K) that Intellia Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Intellia Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Intellia Therapeutics: the Intellia Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.